Post-vaccination SARS-cov-2 infection in nursing home residents, Bordeaux, France.


Journal

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
ISSN: 1873-5967
Titre abrégé: J Clin Virol
Pays: Netherlands
ID NLM: 9815671

Informations de publication

Date de publication:
04 2022
Historique:
received: 19 11 2021
revised: 08 03 2022
accepted: 14 03 2022
pubmed: 22 3 2022
medline: 27 4 2022
entrez: 21 3 2022
Statut: ppublish

Résumé

To describe COVID-19 breakthrough infections in two nursing homes (NHs) sites of active COVID-19 clusters despite optimal vaccination coverage. A cross-sectional study was conducted in two NHs of south-western France, following the investigation of COVID-19 clusters (February-March 2021). SARS-CoV-2-confirmed infection was defined by positive RT-PCR. Antibodies neutralization capacities were tested in a subgroup of fully-vaccinated and seropositive-residents. Of the 152 residents, 66% were female with median age 87 years (IQR: 80.0-90.2). Overall, 132 (87%) residents received 2 doses of vaccine, 14 (9%) one dose and 6 (4%) were unvaccinated. Forty-seven (31%) residents had confirmed infection (45 (98%) with variant 20I/501Y.V1). All 6 non-vaccinated residents, 4 /14 who had one dose and 37/132 that had two doses, were infected. Of the 39 residents reporting symptoms, 12 and 3 presented severe and critical disease, respectively. One resident with a confirmed infection died. Infected-residents had a median anti-S IgG titre of 19 116.0 (IQR: 3 028.0-39 681.8 AU/mL), 19 times higher than that of non-infected vaccinated persons (1,207.0; IQR: 494.0-2,782.0). In the subgroup of 19 residents tested for neutralizing antibodies, the neutralizing titre (50%) was strongly positively correlated with the anti-S IgG titre (correlation coefficient = 0.83), and 1.5 times higher for the infected than non-infected residents [5.9 (IQR: 5.3-6.9) vs. 3.6 (2.9-3.8)]. Institutionalized elderly persons who undergo breakthrough infection develop higher titres of anti-S IgGs, which are strongly correlated with the neutralizing capacity of the antibodies. These results advocate for additional vaccine doses in this population.

Identifiants

pubmed: 35313222
pii: S1386-6532(22)00070-1
doi: 10.1016/j.jcv.2022.105134
pmc: PMC8923035
pii:
doi:

Substances chimiques

COVID-19 Vaccines 0
Immunoglobulin G 0
Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105134

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.

Références

Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
JAMA. 2021 Jul 21;:
pubmed: 34287620
Clin Infect Dis. 2022 Mar 1;74(4):707-710
pubmed: 34050731
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Cell. 2021 Apr 29;184(9):2372-2383.e9
pubmed: 33743213
JAMA Intern Med. 2020 Jun 1;180(6):817-818
pubmed: 32275292

Auteurs

Marion Lartigau (M)

Department of Clinical Gerontology, University Hospital Centre Bordeaux, Bordeaux, France.

Eric Ouattara (E)

Medical Information Department, Medical information Analysis and Coordination Unit (UCAIM-DIM), University Hospital Centre Bordeaux, Bordeaux, France. Electronic address: eric.ouattara@chu-bordeaux.fr.

Camille Tumiotto (C)

Virology Laboratory, University Hospital Centre Bordeaux, Bordeaux, France; CNRS UMR5234, Fundamental Microbiology and Pathogenicity, University Hospital Centre Bordeaux, Bordeaux, France.

Harald Wodrich (H)

CNRS UMR5234, Fundamental Microbiology and Pathogenicity, University Hospital Centre Bordeaux, Bordeaux, France.

Laurent Busson (L)

Virology Laboratory, University Hospital Centre Bordeaux, Bordeaux, France.

Pascale Trimoulet (P)

Virology Laboratory, University Hospital Centre Bordeaux, Bordeaux, France.

Elise Thiel (E)

Department of Clinical Gerontology, University Hospital Centre Bordeaux, Bordeaux, France.

Mahissata Nouzille (M)

Department of Clinical Gerontology, University Hospital Centre Bordeaux, Bordeaux, France.

Maria Dubos (M)

Department of Clinical Gerontology, University Hospital Centre Bordeaux, Bordeaux, France.

Marie-Edith Lafon (ME)

Virology Laboratory, University Hospital Centre Bordeaux, Bordeaux, France; CNRS UMR5234, Fundamental Microbiology and Pathogenicity, University Hospital Centre Bordeaux, Bordeaux, France.

Véronique Gilleron (V)

Medical Information Department, Medical information Analysis and Coordination Unit (UCAIM-DIM), University Hospital Centre Bordeaux, Bordeaux, France; Inserm U1219 / Bordeaux Population Health Research Center, Population Health trAnslational Research (PHARes), Universty of Bordeaux, Bordeaux, France.

Patrick Dehail (P)

Inserm U1219 / IRD, University Hospital Centre Bordeaux, Bordeaux, France; Nouvelle-Aquitaine Regional Health Agency, Bordeaux, France.

Nathalie Salles (N)

Department of Clinical Gerontology, University Hospital Centre Bordeaux, Bordeaux, France. Electronic address: nathalie.salles@chu-bordeaux.fr.

Denis Malvy (D)

Department of Infectious Diseases and Tropical Medicine, Division of Tropical Medicine and Clinical International Health, University Hospital Centre Bordeaux, Bordeaux, France; Inserm U1219 / IRD, University Hospital Centre Bordeaux, Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH